Press release
Investgiation announced for Long-Term Investors in Eyenovia, Inc. (NASDAQ: EYEN) who lost money
An investigation on behalf of investors in Eyenovia, Inc. (NASDAQ: EYEN) shares over potential wrongdoing at Eyenovia, Inc. was an
Investors who purchased shares of Eyenovia, Inc. (NASDAQ: EYEN) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm concerns whether certain Eyenovia, Inc. directors breached their fiduciary duties and caused damage to the company and its shareholders.
New York based Eyenovia, Inc., a clinical stage biopharmaceutical company, engages in developing a pipeline of ophthalmology products in the United States. Eyenovia, Inc. went public in January 2018.
Since then shares of Eyenovia, Inc. (NASDAQ: EYEN) declined from $10.74 per share on January 25, 2018 to as low as $3.99 per share on May 09, 2023.
Those who purchased shares of Eyenovia, Inc. (NASDAQ: EYEN) have certain options and should contact the Shareholders Foundation.
Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Investgiation announced for Long-Term Investors in Eyenovia, Inc. (NASDAQ: EYEN) who lost money here
News-ID: 3235467 • Views: …
More Releases from Shareholders Foundation
Lawsuit Alert: Investors who lost money with James Hardie Industries plc (NYSE: …
An investor, who purchased shares of James Hardie Industries plc (NYSE: JHX), filed a lawsuit over alleged violations of Federal Securities Laws by James Hardie Industries plc in connection with certain allegedly false and misleading statements.
Investors who purchased shares of James Hardie Industries plc (NYSE: JHX) have certain options and for certain investors are short and strict deadlines running. Deadline: December 23, 2025. NYSE: JHX investors should contact the Shareholders…
Investigation announced for Long-Term Investors in SelectQuote, Inc. (NYSE: SLQT …
An investigation on behalf of current long-term investors in shares of SelectQuote, Inc. (NYSE: SLQT) concerning potential breaches of fiduciary duties by certain directors and officers of SelectQuote, Inc. was announced.
Investors who are current long term investors in SelectQuote, Inc. (NYSE: SLQT) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term…
Lawsuit filed for Investors who lost money with shares of MoonLake Immunotherape …
An investor, who purchased shares of MoonLake Immunotherapeutics (NASDAQ: MLTX), filed a lawsuit over alleged violations of Federal Securities Laws by MoonLake Immunotherapeutics in connection with certain allegedly false and misleading statements.
Investors who purchased a significant amount of shares of MoonLake Immunotherapeutics (NASDAQ: MLTX) between March 10, 2024 and September 29, 2025, have certain options and for certain investors are short and strict deadlines running. Deadline: December 15, 2025. NASDAQ:…
Dow Inc. (NYSE: DOW) Investor Alert: Deadline in Lawsuit on October 28, 2025
A deadline is coming up on October 28, 2025 in the lawsuit filed for certain investors of Dow Inc. (NYSE: DOW) over alleged securities laws violations by Dow Inc.
Investors who purchased shares of Dow Inc. (NYSE: DOW) have certain options and there are strict and short deadlines running. Deadline: October 28, 2025. Dow Inc. (NYSE: DOW) stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 -…
More Releases for Eyenovia
Mydriasis Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | …
The Key Mydriasis Companies in the market include - Viatris/Ocuphire Pharma, Eyenovia, Rayner Surgical/Omeros, Eyenovia Inc., Taejoon Pharmaceutical Co., Ltd., and others.
DelveInsight's "Mydriasis Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Mydriasis, historical and forecasted epidemiology as well as the Mydriasis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
The latest healthcare forecast report provides an in-depth analysis…
Presbyopia Treatment Market Future Business Opportunities 2025-2032 | AbbVie, Ey …
The presbyopia treatment market is estimated to be valued at USD 20.17 Bn in 2025 and is expected to reach USD 29.54 Bn by 2032, growing at a compound annual growth rate (CAGR) of 5.6% from 2025 to 2032.
According to the latest research from CoherentMI, the Presbyopia Treatment Market is projected to experience significant growth between 2025 and 2032. This market intelligence report offers in-depth analysis based on thorough…
Presbyopia Treatment Market Future Business Opportunities 2025-2032 | AbbVie,Eye …
The presbyopia treatment market is estimated to be valued at USD 19.1 Bn in 2024 and is expected to reach USD 26.4 Bn by 2031, growing at a compound annual growth rate (CAGR) of 5.4% from 2024 to 2031.
The release of the report "Presbyopia Treatment Market 2025 by Manufacturers, Regions, Type and Application, Forecast to 2032". This includes examining past deployments, current market conditions, and expected future deployments.…
Mydriasis Market Predicted to See Upsurge Through 2034, Highlights DelveInsight …
The Key Mydriasis Companies in the market include - Viatris/Ocuphire Pharma, Eyenovia, Rayner Surgical/Omeros, Eyenovia Inc., Taejoon Pharmaceutical Co., Ltd., and others.
DelveInsight's "Mydriasis Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Mydriasis, historical and forecasted epidemiology as well as the Mydriasis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
The latest healthcare forecast report provides an in-depth analysis…
Mydriasis Pipeline 2024: Clinical Trials Assessment, FDA Approvals, Therapies, a …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Mydriasis pipeline constitutes 3+ key companies continuously working towards developing 3+ Mydriasis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Mydriasis Pipeline Insight, 2024 [https://www.delveinsight.com/sample-request/mydriasis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Mydriasis Market.
The Mydriasis Pipeline report embraces in-depth commercial and clinical…
Mydriasis Market Forecasted to Surge in Coming Years, 2024-2034 Analysis by Delv …
DelveInsight's "Mydriasis Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Mydriasis, historical and forecasted epidemiology as well as the Mydriasis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
The latest healthcare forecast report provides an in-depth analysis of Mydriasis, offering comprehensive insights into the Mydriasis revenue trends, prevalence, and treatment landscape. The report delves into key Mydriasis…
